Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

28 Apr 2017 15:37

RNS Number : 7478D
Mereo BioPharma Group plc
28 April 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Mereo BioPharma Group plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Novartis Pharma AG

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

27 April 2017

6. Date on which issuer notified:

27 April 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

19%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary shares

of £0.03 each

 

GB00BZ4G2K23

12,546,480

18.1%

13,767,841

19.5%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

13,767,841

19.5%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Marc Ceulemans

15. Contact telephone number:

00 41 61 324 5365

 

Note: Annex should only be submitted to the FCA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Contact address

(registered office for legal entities)

 

Phone number & email

 

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Contact address

 

Phone number & email

 

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FCA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLIPMITMBJTBIR
Date   Source Headline
4th May 20177:00 amRNSInitiation of BPS-804 Phase 2b study
28th Apr 20173:37 pmRNSHolding(s) in Company
28th Apr 201712:53 pmRNSHolding(s) in Company
28th Apr 201710:05 amRNSHolding(s) in Company
26th Apr 20177:00 amRNSConversion of loan note and issue of equity
24th Apr 20176:07 pmRNSHolding(s) in Company
5th Apr 20177:00 amRNSGrant of Options and Awards
3rd Apr 20177:00 amRNSResults of Placing
31st Mar 20175:54 pmRNSResults of Placing
29th Mar 201712:30 pmRNSProposed Placing
15th Mar 20177:00 amRNSPosting of Annual Report and Notice of AGM
7th Mar 20177:00 amRNSPositive recommendation for BGS-649 Phase 2b trial
27th Feb 20177:00 amRNSPreliminary Results
20th Feb 20177:00 amRNSEMA Adaptive Pathways programme accepts BPS-804
23rd Jan 20177:05 amRNSPresentation at Shares Spotlight Evening
23rd Jan 20177:00 amRNSThree abstracts accepted for ATS Meeting
12th Jan 20177:01 amRNSDirectorate update
5th Jan 201712:00 pmRNSMereo BioPharma to Present at Biotech Showcase
12th Dec 20167:00 amRNSBusiness Update
7th Nov 20167:10 amRNSAppointment of Chief Financial Officer
3rd Nov 20167:00 amRNSPositive Phase 1 interaction study with BCT-197
5th Oct 20167:00 amRNSDirectorate Change
16th Sep 20167:00 amRNSHalf-year Report
9th Aug 20164:04 pmRNSNotice of Results
18th Jul 20161:25 pmRNSResult of AGM
30th Jun 20167:00 amRNSBPS-804 granted EU orphan drug status
24th Jun 201612:47 pmRNSNotice of AGM
9th Jun 20161:17 pmRNSDirector/PDMR Shareholding
9th Jun 20168:01 amRNSFirst Day of Dealings on AIM
10th Nov 20086:21 pmRNSFurther re financial position
4th Nov 20083:01 pmRNSStatement re suspension
4th Nov 20083:00 pmRNSSuspension
23rd Oct 20084:35 pmRNSHolding(s) in Company
23rd Oct 20082:25 pmRNSAGM Statement
2nd Oct 20083:14 pmRNSHolding(s) in Company
23rd Sep 200810:02 amRNSNotice of AGM
1st Sep 200810:06 amRNSHolding(s) in Company
29th Aug 20083:20 pmRNSResult of GM and Interim Mana
26th Aug 200810:13 amRNSHolding(s) in Company
19th Aug 20082:22 pmRNSHolding(s) in Company
14th Aug 20084:23 pmRNSHolding(s) in Company
13th Aug 200811:00 amRNSDirectorate Change
8th Aug 200811:14 amRNSHolding(s) in Company
8th Aug 200811:03 amRNSHolding(s) in Company
7th Aug 20084:46 pmRNSHolding(s) in Company
6th Aug 20084:41 pmRNSSecond Price Monitoring Extn
6th Aug 20084:36 pmRNSPrice Monitoring Extension
6th Aug 20083:17 pmRNSDirector/PDMR Shareholding
6th Aug 20087:08 amRNSFundraising and New Board App
6th Aug 20087:05 amRNSNew Joint Venture

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.